Your browser doesn't support javascript.
loading
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects.
Yang, Xin-Mei; Yang, Yang; Yao, Bu-Fan; Ye, Pan-Pan; Xu, Yan; Peng, Shao-Ping; Yang, Yu-Mei; Shu, Pan; Li, Pei-Jin; Li, Shan; Hu, Hong-Lin; Li, Qian; Song, Lin-Lin; Chen, Ke-Guang; Zhou, Hai-Yan; Zhang, Ye-Hui; Zhao, Fu-Rong; Tang, Bo-Hao; Zhang, Wei; Zhang, Xin-Fang; Fu, Shu-Meng; Hao, Guo-Xiang; Zheng, Yi; Shen, Jing-Shan; Xu, Ye-Chun; Jiang, Xiang-Rui; Zhang, Lei-Ke; Tang, Ren-Hong; Zhao, Wei.
Affiliation
  • Yang XM; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Yang Y; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Yao BF; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Ye PP; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Xu Y; Simcere of America, Cambridge, MA, USA.
  • Peng SP; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Yang YM; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Shu P; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Li PJ; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Li S; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Hu HL; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Li Q; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Song LL; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Chen KG; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Zhou HY; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Zhang YH; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Zhao FR; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
  • Tang BH; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Zhang W; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Zhang XF; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Fu SM; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Hao GX; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Zheng Y; Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China.
  • Shen JS; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.
  • Xu YC; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.
  • Jiang XR; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.
  • Zhang LK; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, PR China.
  • Tang RH; Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, PR China.
  • Zhao W; Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jin
Eur J Pharm Sci ; 191: 106598, 2023 Dec 01.
Article in En | MEDLINE | ID: mdl-37783378
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protease Inhibitors / COVID-19 Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Eur J Pharm Sci Journal subject: FARMACIA / FARMACOLOGIA / QUIMICA Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protease Inhibitors / COVID-19 Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Eur J Pharm Sci Journal subject: FARMACIA / FARMACOLOGIA / QUIMICA Year: 2023 Document type: Article